NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01773187,Pacritinib Versus Best Available Therapy to Treat Myelofibrosis,https://clinicaltrials.gov/study/NCT01773187,,TERMINATED,"Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.",YES,Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis,DRUG: Pacritinib|DRUG: Best Available Therapy,"Spleen Volume Reduction, Number of patients achieving a â‰¥ 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT), Baseline to Week 24","Total Symptom Score (TSS) Reduction, Number of patients with \>= 50% reduction in total score from baseline to week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0 (MPN-SAF TSS 2.0). Responses (on a scale from 0 \[absent\] to 10 \[worst imaginable\]) to questions about symptoms (tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under the ribs on the left side) were used to calculate the TSS., Baseline to Week 24",,CTI BioPharma,,ALL,"ADULT, OLDER_ADULT",PHASE3,327,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,PERSIST-1 (PAC325),2013-01,2015-01,2016-04,2013-01-23,2020-09-29,2020-09-29,"CTI Investigational Site 10002, Scottsdale, Arizona, 85259, United States|CTI Investigational Site 10004, Omaha, Nebraska, 68198, United States|CTI Investigational Site 10001, Morristown, New Jersey, 07962, United States|CTI Investigational Site 10003, Greenville, South Carolina, 29601, United States|CTI Investigational Site 61006, Box Hill, Australia|CTI Investigational Site 61001, Coffs Harbour, Australia|CTI Investigational Site 61005, Geelong, Australia|CTI Investigational Site 61003, Gosford, Australia|CTI Investigational Site 61004, Hobart, Australia|CTI Investigational Site 61002, Milton, Australia|CTI Investigational Site 32002, Antwerp, Belgium|CTI Investigational Site 32003, Antwerp, Belgium|CTI Investigational Site 32001, Brugge, Belgium|CTI Investigational Site 32005, Bruxelles, Belgium|CTI Investigational Site 32004, La Louviere, Belgium|CTI Investigational Site 42003, Brno, Czechia|CTI Investigational Site 42001, Olomouc, Czechia|CTI Investigational Site 42002, Plzen, Czechia|CTI Investigational Site 42004, Prague, Czechia|CTI Investigational Site 33005, Amiens, France|CTI Investigational Site 33006, Caen, France|CTI Investigational Site 33011, Grenoble, France|CTI Investigational Site 33012, Lens, France|CTI Investigational Site 33007, Lille, France|CTI Investigational Site 33001, Nimes Cedex, France|CTI Investigational Site 33004, Paris, France|CTI Investigational Site 33008, Paris, France|CTI Investigational Site 33009, Pessac, France|CTI Investigational Site 33010, Pierre Benite, France|CTI Investigational Site 33003, Strasbourg, France|CTI Investigational Site 33002, Toulouse, France|CTI Investigational Site 49006, Berlin, Germany|CTI Investigational Site 49007, Berlin, Germany|CTI Investigational Site 49003, Dresden, Germany|CTI Investigational Site 49008, Essen, Germany|CTI Investigational Site 49002, Freiburg, Germany|CTI Investigational Site 49001, Koln, Germany|CTI Investigational Site 49005, Mainz, Germany|CTI Investigational Site 49004, Munchen, Germany|CTI Investigational Site 49009, Munster, Germany|CTI Investigational Site 36002, Budapest, Hungary|CTI Investigational Site 36005, Debrecen, Hungary|CTI Investigational Site 36006, Gyula, Hungary|CTI Investigational Site 36003, Kaposvar, Hungary|CTI Investigational Site 36004, Kecskemet, Hungary|CTI Investigational Site 36001, Szeged, Hungary|CTI Investigational Site 36008, Szolnok, Hungary|CTI Investigational Site 36007, Szombathely, Hungary|CTI Investigational Site 39003, Bologna, Italy|CTI Investigational Site 39001, Firenze, Italy|CTI Investigational Site 39005, Milano, Italy|CTI Investigational Site 39004, Monza, Italy|CTI Investigational Site 39002, Padova, Italy|CTI Investigational Site 39008, Reggio Emilia, Italy|CTI Investigational Site 39006, Rimini, Italy|CTI Investigational Site 31001, Amsterdam, Netherlands|CTI Investigational Site 31002, Maastricht, Netherlands|CTI Investigational Site 31003, Rotterdam, Netherlands|CTI Investigational Site 31004, Utrecht, Netherlands|CTI Investigational Site 64001, Christchurch, New Zealand|CTI Investigational Site 64004, Dunedin, New Zealand|CTI Investigational Site 64002, Hamilton, New Zealand|CTI Investigational Site 64003, Takapuna, New Zealand|CTI Investigational Site 70011, Izhevsk, Russian Federation|CTI Investigational Site 70008, Moscow, Russian Federation|CTI Investigational Site 70009, Moscow, Russian Federation|CTI Investigational Site 70002, Petrozavodsk, Russian Federation|CTI Investigational Site 70010, Saint Petersburg, Russian Federation|CTI Investigational Site 70005, Samara, Russian Federation|CTI Investigational Site 70006, Sochi, Russian Federation|CTI Investigational Site 70001, St. Petersburg, Russian Federation|CTI Investigational Site 70004, St. Petersburg, Russian Federation|CTI Investigational Site 70007, Volgograd, Russian Federation|CTI Investigational Site 44004, Birmingham, United Kingdom|CTI Investigational Site 44008, Bournemouth, United Kingdom|CTI Investigational Site 44002, Cambridge, United Kingdom|CTI Investigational Site 44003, Cardiff, United Kingdom|CTI Investigational Site 44001, London, United Kingdom|CTI Investigational Site 44007, London, United Kingdom|CTI Investigational Site 44006, Manchester, United Kingdom|CTI Investigational Site 44005, Oxford, United Kingdom",
